Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
Ribon Therapeutics, 35 Cambridgepark Drive, Suite 300, Cambridge, MA 02140, USA.
Cell Chem Biol. 2020 Jul 16;27(7):877-887.e14. doi: 10.1016/j.chembiol.2020.06.009.
Poly(ADP-ribose) polymerase (PARP) enzymes use nicotinamide adenine dinucleotide (NAD) to modify up to seven different amino acids with a single mono(ADP-ribose) unit (MARylation deposited by PARP monoenzymes) or branched poly(ADP-ribose) polymers (PARylation deposited by PARP polyenzymes). To enable the development of tool compounds for PARP monoenzymes and polyenzymes, we have developed active site probes for use in in vitro and cellular biophysical assays to characterize active site-directed inhibitors that compete for NAD binding. These assays are agnostic of the protein substrate for each PARP, overcoming a general lack of knowledge around the substrates for these enzymes. The in vitro assays use less enzyme than previously described activity assays, enabling discrimination of inhibitor potencies in the single-digit nanomolar range, and the cell-based assays can differentiate compounds with sub-nanomolar potencies and measure inhibitor residence time in live cells.
聚(ADP-核糖)聚合酶(PARP)酶利用烟酰胺腺嘌呤二核苷酸(NAD)将多达七个不同的氨基酸修饰为单个单(ADP-核糖)单元(由 PARP 单酶沉积的 MARylation)或支化聚(ADP-核糖)聚合物(由 PARP 多酶沉积的 PARylation)。为了能够开发 PARP 单酶和多酶的工具化合物,我们已经开发了活性位点探针,用于体外和细胞生物物理测定,以表征与 NAD 结合竞争的活性位点定向抑制剂。这些测定与每个 PARP 的蛋白质底物无关,克服了对这些酶的底物的普遍缺乏了解。体外测定比以前描述的活性测定使用更少的酶,能够区分抑制剂在十纳摩尔范围内的效力,并基于细胞的测定可以区分具有亚纳摩尔效力的化合物,并测量抑制剂在活细胞中的停留时间。